TNF inhibitors are being used in a rapidly expanding number of rheumatoid arthritis (RA) patients due to their effectiveness and acceptable safety profiles. To date, concerns regarding the adverse effects of TNF inhibitors have focused on infections, hematologic malignancies, and demyelinating disorders. Recently, the development of autoantibodies and other autoimmunity has been increasingly reported. Here, we describe a 36-year-old RA patient in whom organizing pneumonia and systemic lupus erythematosus were detected during etanercept treatment.
机构:
St Lukes Int Hosp, Div Pulm Med, Thorac Ctr, 9-1 Akashi Cho, Chuo City, Tokyo 1048560, JapanSt Lukes Int Hosp, Div Pulm Med, Thorac Ctr, 9-1 Akashi Cho, Chuo City, Tokyo 1048560, Japan
Imai, R.
Jinta, T.
论文数: 0引用数: 0
h-index: 0
机构:
St Lukes Int Hosp, Div Pulm Med, Thorac Ctr, 9-1 Akashi Cho, Chuo City, Tokyo 1048560, JapanSt Lukes Int Hosp, Div Pulm Med, Thorac Ctr, 9-1 Akashi Cho, Chuo City, Tokyo 1048560, Japan